Previous Page  255 / 320 Next Page
Information
Show Menu
Previous Page 255 / 320 Next Page
Page Background

659

JD, Thorell EA, et al. Considerations in the pharmacologic treatment

and prevention of neonatal sepsis. Paediatr Drugs. 2014;16:67–

81.

23. Young TE. Therapeutic drug monitoring--the appropriate use of

drug level measurement in the care of the neonate. Clin Perinatol.

2012;39(1):25–31.

24. Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug

interactions. Curr Clin Pharmacol. 2006;1:5–20.

25. Morales-Olivas FJ, Estañ L. [Drug-drug interactions. An update].

Med clínica [Internet]. 2006;127:269–75.

26. Anderson GD, Lynn AM. Optimizing pediatric dosing: a

developmental pharmacologic approach. Pharmacotherapy.

2009;29:680–90.

27. Tayman C, Rayyan M, Allegaert K. Neonatal pharmacology:

extensive interindividual variability despite limited size. J Pediatr

Pharmacol Ther. 2011;16:170–84.

28. Johnson PN, Miller JL, Hagemann TM. Sedation and analgesia in

critically ill children. AACN Adv Crit Care. 2012;23:415–34.

29. Yee DL, O’Brien SH, Young G. Pharmacokinetics and

pharmacodynamics of anticoagulants in paediatric patients. Clin

Pharmacokinet. 2013;52:967–80.

30. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and

bone health. Arch Dis Child. 2002;87:93–6.

31. Cohlan SQ, Bevelander G, Tiamsic T, Rall DP, Milch RA, Milch RA, et

al. Growth Inhibition of Prematures Receiving Tetracycline. Am J Dis

Child. 1963;105:453-461.

32. Patel K, Goldman JL. Safety Concerns Surrounding Quinolone Use

in Children. J Clin Pharmacol. 2016; doi: 10.1002/jcph.715.

[Epub ahead of print]

33. Roberts J, Lipman J. Pharmacokinetic issues for antibiotics in the

critically ill patient. Crit Care Med. 2009;37:840–51.

34. Udy A, Roberts J, Boots RJ, Paterson DL, Lipman J. Augmented renal

clearance: implications for antibacterial dosing in the critically ill.

Clin Pharmacokinet. 2010;49:1–16.

35. Lortholary O, Lefort A, Tod M, Chomat A, Darras-joly C, Cordonnier

C, et al. Pharmacodynamics and pharmacokinetics of antibacterial

drugs in the management of febrile neutropenia. Lancet Infect Dis.

2008;8:612–20.

36. Kremer TM, Zwerdling RG, Michelson PH, O’Sullivan P. Intensive

care management of the patient with cystic fibrosis. J Intensive

Care Med. 2008;23:159–77.

37. Assadi F, Sharbaf FG. Practical considerations to drug dosing in

children with acute kidney injury. J Clin Pharmacol. 2016;56:399–

407.

38. Kendrick JG, Carr RR, Ensom MHH. Pediatric Obesity:

Pharmacokinetics and Implications for Drug Dosing. Clin Ther.

2015;37:1897–923.

39. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential

drug-drug interactions in infant, child, and adolescent patients in

children’s hospitals. Pediatrics. 2015;135:e99–108.

40. Siddiqi A, Khan DA, Khan FA, Razzaq A. Therapeutic drug

monitoring of amikacin in preterm and term infants. Singapore

Med J. 2009;50:486–9.

41. Pauwels S, Allegaert K. Therapeutic drug monitoring in neonates.

Arch Dis Child. 2016;101:377–81.

42. Morales-Carpi C, Julve Chover N, Carpi Lobatón R, Estañ L,

Rubio E, Lurbe E, et al. Medicamentos utilizados en pediatría

extrahospitalaria: ¿disponemos de información suficiente? An

Pediatría. 2008;68:439–46.

43. Viada C, Ballagas C, Blanco Y. Ética en la investigación con

poblaciones especiales. Rev Cuba Invest Biomed. 2001;20:140–9.

44. Benjamin DK, Smith PB, Murphy MD, Roberts R, Mathis L, Avant

D, et al. Peer-reviewed publication of clinical trials completed for

pediatric exclusivity. JAMA. 2006;296:1266–73.

45. Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G, et

al. Improving Pediatric Dosing Through Pediatric Initiatives: What

We Have Learned. Pediatrics. 2008;121:530–9.

46. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed

medicine use and adverse drug reactions in children: a narrative

review of the literature. Eur J Clin Pharmacol. 2012;68:21–8.

47. Choonara I, Conroy S. Unlicensed and off-label drug use in children:

implications for safety. Drug Saf. 2002;25(1):1–5.

48. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin

Pharmacol Ther. 2012;91:796–801.

49. Milne C-P, Bruss JB. The economics of pediatric formulation

development for off-patent drugs. Clin Ther. 2008;30:2133–45.

50. Nahata MC, Allen L V. Extemporaneous drug formulations. Clin

Ther. 2008;30:2112–9.

51. Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug

reactions and off-label and unlicensed medicines in children: a

prospective cohort study of unplanned admissions to a paediatric

hospital. Br J Clin Pharmacol. 2014;77:545–53.

52. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher

W, et al. The impact of unlicensed and off-label drug use on adverse

drug reactions in paediatric patients. Drug Saf. 2004;27:1059–

67.

53. Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in

newborns, infants and toddlers: pediatric pharmacovigilance

between present and future. Expert Opin Drug Saf. 2012;11:95–

105.

54. Castro-Pastrana LI, Carleton BC. Improving pediatric drug safety:

need for more efficient clinical translation of pharmacovigilance

knowledge. J Popul Ther Clin Pharmacol. 2011;18:e76–88.

55. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C,

Bonati M. Incidence of adverse drug reactions in paediatric in/

out-patients: a systematic review andmeta-analysis of prospective

studies. Br J Clin Pharmacol. 2001;52:77–83.

56. Aagaard L, Christensen A, Hansen EH. Information about adverse

drug reactions reported in children: a qualitative review of

empirical studies. Br J Clin Pharmacol. 2010;70:481–91.

57. Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R,

et al. Adverse drug reactions in children--a systematic review. PLoS

One. 2012;7:e24061.

58. Star K, Edwards IR. Pharmacovigilance for children’s sake. Drug Saf.

2014;37:91–8.

59. González-Martin G, Caroca CM, Paris E. Adverse drug reactions

(ADRs) in hospitalized pediatric patients. A prospective study. Int J

Clin Pharmacol Ther. 1998;36:530–3.

[FARMACOLOGÍA DEL PACIENTE PEDIÁTRICO - Q.F. Claudio González]